GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » Cash Flow from Financing

HeartBeam (HeartBeam) Cash Flow from Financing : $24.48 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is HeartBeam Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, HeartBeam paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, HeartBeam spent $0.00 Mil on financial activities for the three months ended in Mar. 2024.


HeartBeam Cash Flow from Financing Historical Data

The historical data trend for HeartBeam's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartBeam Cash Flow from Financing Chart

HeartBeam Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
0.21 0.62 16.40 0.35 24.99

HeartBeam Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 24.37 0.11 - -

HeartBeam Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

HeartBeam's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

HeartBeam's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartBeam  (NAS:BEAT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

HeartBeam's issuance of stock for the three months ended in Mar. 2024 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

HeartBeam's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

HeartBeam's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. HeartBeam received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

HeartBeam's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. HeartBeam paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

HeartBeam's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. HeartBeam received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

HeartBeam's other financing for the three months ended in Mar. 2024 was $0.00 Mil. HeartBeam received $0.00 Mil on other financial activities.


HeartBeam Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of HeartBeam's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartBeam (HeartBeam) Business Description

Traded in Other Exchanges
N/A
Address
2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Its initial focus is providing diagnostic data to help physicians with the care management of patients with cardiovascular disease.
Executives
Urioste George De director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen officer: Chief Technology Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno officer: President 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein officer: Chief Financial Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel officer: Chief Operating Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard M Ferrari director, officer: Exec Chm of the BOD 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic 10 percent owner, officer: Chief Executive Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink director 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt officer: Chief Business Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050